Shopping Cart
Remove All
Your shopping cart is currently empty
dASK1-VHL is an orally active PROTAC degrader targeting ASK1. It effectively binds to VHL, promoting the selective degradation of ASK1. By reducing ASK1 protein levels, dASK1-VHL inhibits the activation of p38 MAPK and decreases liver lipid content, offering new insights for MASH research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | dASK1-VHL is an orally active PROTAC degrader targeting ASK1. It effectively binds to VHL, promoting the selective degradation of ASK1. By reducing ASK1 protein levels, dASK1-VHL inhibits the activation of p38 MAPK and decreases liver lipid content, offering new insights for MASH research. |
| In vitro | dASK1-VHL (Compound dASK1-VHL) induces efficient and specific degradation of ASK1 in HepG2 cells via the VHL E3 ligase, within a concentration range of 1-1000 nM over an 8-hour period. |
| In vivo | Compound dASK1-VHL, administered at 2 mg/kg via intraperitoneal injection once daily for 14 days, degrades ASK1 through the ubiquitin-proteasome pathway, significantly improving the pathological features of MASH in C57/Bl6 mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.